{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/REGN/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T07:58:46.410Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8466,"canonical_name":"REGENERON PHARMACEUTICALS, INC.","cik":"0000872589","uei":null,"lei":null,"duns":null,"ticker":"REGN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":4,"clinical":49,"open":1,"dol":1},"count":55,"timeline":[{"ts":"2026-07-06","kind":"sec.filing","form_type":"8-K","title":"8-K — REGENERON PHARMACEUTICALS, INC. — 2026-07-06","url_slug":"/sec/cik-0000872589/8-k/0001104659-26-080562","accession_number":"0001104659-26-080562","importance":35},{"ts":"2026-07-02","kind":"sec.form144","reporter":"Arthur F. Ryan","title":"Director","shares":400,"usd_value":249888,"security_title":"Common Stock","approx_sale_date":"2026-07-02","accession_number":"0001968582-26-000693","importance":40.0499776},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"RYAN ARTHUR F","title":null,"shares":200,"price_per_share":650.15,"usd_value":130030,"security_title":"Common Stock","importance":35.13003},{"ts":"2026-06-17","kind":"sec.filing","form_type":"8-K","title":"8-K — REGENERON PHARMACEUTICALS, INC. — 2026-06-17","url_slug":"/sec/cik-0000872589/8-k/0001104659-26-075127","accession_number":"0001104659-26-075127","importance":35},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT03409614","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":70},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07594106","excerpt":"[\"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\"Clear Cell Renal Cell Carcinoma (ccRCC)\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07594093","excerpt":"[\"Overweight or Obesity\"]","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07154745","excerpt":"[\"Paroxysmal Nocturnal Hemoglobinuria\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization","security_title":"PHASE4","status":"NOT_YET_RECRUITING","accession_number":"NCT07587658","excerpt":"[\"Chronic Obstructive Pulmonary Disease (COPD)\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05828511","excerpt":"[\"Multiple Myeloma\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06787612","excerpt":"[\"Ovarian Cancer\",\"Fallopian Tube Cancer\",\"Primary Peritoneal Cancer\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe","security_title":null,"status":"RECRUITING","accession_number":"NCT05363319","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":25},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06230224","excerpt":"[\"B-Cell Non-Hodgkin Lymphoma (B-NHL)\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT06602726","excerpt":"[\"Allergic Conjunctivitis\"]","importance":70},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07222761","excerpt":"[\"Relapsed and/or Refractory Multiple Myeloma (RRMM)\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06299098","excerpt":"[\"Obesity\"]","importance":45},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT03564340","excerpt":"[\"Recurrent Ovarian Cancer\",\"Recurrent Fallopian Tube Cancer\",\"Recurrent Primary Peritoneal Cancer\",\"Recurrent Endometrial Cancer\",\"Endometrial Cancer\",\"Low-grade Serous Ovarian Cancer\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07154290","excerpt":"[\"Advanced/Metastatic Non-Small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT05519475","excerpt":"[\"Metabolic Dysfunction-Associated SteatoHepatitis (MASH)\"]","importance":45},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07213778","excerpt":"[\"Symptomatic Venous Thromboembolism (VTE)\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07220785","excerpt":"[\"Generalized Lipodystrophy\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06246916","excerpt":"[\"Melanoma\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05557591","excerpt":"[\"Advanced Non-Small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05788536","excerpt":"[\"Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)\"]","importance":45},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06369467","excerpt":"[\"Food Allergy\"]","importance":30},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06593600","excerpt":"[\"Postural Orthostatic Tachycardia Syndrome (POTS)\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)","security_title":"PHASE1,PHASE2","status":"COMPLETED","accession_number":"NCT04083534","excerpt":"[\"Relapsed Multiple Myeloma\",\"Refractory Multiple Myeloma\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05685173","excerpt":"[\"B-cell Non-Hodgkins Lymphoma (B-NHL)\"]","importance":30},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05133531","excerpt":"[\"Paroxysmal Nocturnal Hemoglobinuria\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07430956","excerpt":"[\"Atrial Fibrillation (AF)\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07431086","excerpt":"[\"Overweight or Obesity\"]","importance":45},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06292780","excerpt":"[\"Relapsed/Refractory Systemic Light Chain Amyloidosis\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07318597","excerpt":"[\"Pulmonary Arterial Hypertension (PAH)\"]","importance":45},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06836609","excerpt":"[\"Metabolic Dysfunction-Associated Steatotic Liver Disease\",\"Metabolic Dysfunction-Associated Steatohepatitis\"]","importance":45},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05352672","excerpt":"[\"Melanoma\"]","importance":60},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06585410","excerpt":"[\"Cutaneous Squamous Cell Carcinoma (CSCC)\"]","importance":60},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT06572228","excerpt":"[\"Asthma\"]","importance":25},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT06602739","excerpt":"[\"Allergic Conjunctivitis\"]","importance":70},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT03761108","excerpt":"[\"Multiple Myeloma\"]","importance":45},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant","security_title":null,"status":"RECRUITING","accession_number":"NCT05106387","excerpt":"[\"Chronic Kidney Disease (CKD)\"]","importance":25},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05648214","excerpt":"[\"Healthy Volunteers\",\"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)\"]","importance":45},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06379789","excerpt":"[\"Hemophilia B\"]","importance":45},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07527923","excerpt":"[\"Healthy Volunteer\",\"Atopic Dermatitis\"]","importance":30},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07216066","excerpt":"[\"Parkinsons Disease\"]","importance":30},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06669247","excerpt":"[\"Relapsed/Refractory Multiple Myeloma\"]","importance":45},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06975787","excerpt":"[\"Lupus Nephritis (LN)\"]","importance":30},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07526116","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07410117","excerpt":"[\"Cancer-Associated Thrombosis (CAT)\"]","importance":60},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT04626635","excerpt":"[\"Advanced Solid Tumors\"]","importance":45},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06140524","excerpt":"[\"Monoclonal Gammopathy of Undetermined Significance (MGUS)\",\"Smoldering Multiple Myeloma (SMM)\"]","importance":45},{"ts":"2026-04-07","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06548100","excerpt":"[\"Generalized Lipodystrophy\"]","importance":60},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03916627","excerpt":"[\"Non-small Cell Lung Cancer\",\"Hepatocellular Carcinoma\",\"Head and Neck Squamous Cell Carcinoma\"]","importance":45},{"ts":"2026-03-31","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Compassionate Use of Ubamatamab","security_title":null,"status":"AVAILABLE","accession_number":"NCT07502716","excerpt":"[\"Renal Medullary Carcinoma (RMC)\",\"Epithelioid Sarcoma\"]","importance":25},{"ts":"2024-12-31","kind":"open.payments","reporter":"Regeneron Pharmaceuticals, Inc.","title":"$7655742.0 to 1614 physicians (2024–2024)","security_title":"manufacturer","excerpt":"LIBTAYO","accession_number":"2024","usd_value":7655742,"importance":70},{"ts":"2024-12-31","kind":"dol.form5500","reporter":"REGENERON PHARMACEUTICALS, INC.","title":"REGENERON PHARMACEUTICALS, INC. WELFARE BENEFIT PLAN","security_title":"Welfare: 4A4B4D4E4F4G4H4L4Q","excerpt":"Total participants 10959 · plan number 501","accession_number":"20250808094158NAL0013043778001","importance":60}]}